Welcome to Oxford Immunotec’s knowledge hub, where you will find insightful and up to date resources for you, the healthcare professional, connecting the dots between TB and COVID-19 and highlighting the importance of TB testing in a COVID-19 environment.

Com-COV study finds mixing COVID-19 vaccines gives good protection, with strongest T cell activity seen in people who had Oxford jab followed by Pfizer booster.

Oxford vaccine group comment on their latest PITCH study which finds that previous infection, whether symptomatic or asymptomatic does not protect from long-term COVID-19.

Boston scientists discuss findings from their recent study which may lead to more effective COVID-19 vaccines by stimulating T cells.

SARS-CoV-2 UK variant may induce more inflammation study suggests.

Individuals who have been infected with the SARS-CoV-2 virus still have detectable T cell responses 6 months after initial infection.

Meta-analysis shows SARS-CoV-2 variants unlikely to affect T cell responses.

Large scale expansion of spike-reactive T cells feasible after Covid vaccination.

AstraZeneca and Pfizer vaccines induce T cell reactivity against multiple SARS-CoV-2 variants.

The Protective Immunity from T cells to Covid-19 in Health workers (PITCH) study finds strong T cell and antibody responses following one dose of Pfizer vaccine.

Functional T cell responses remain robust up to 6 months after infection with SARS-CoV-2, whilst some antibody responses may begin to decline.

Study examines BNT162b2 post-vaccination T cell responses using Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 kit

Study shows that that T cell responses in convalescent COVID-19 subjects or mRNA vaccine recipients are not substantially affected by mutations

This study suggests that individuals who have recovered from, or been vaccinated against SARS-CoV-2 should maintain effective CD8+ T cells responses against the major variants of the virus that have recently emerged.

COVID-19 disease duration and severity was associated with the late emergence of SARS-CoV-2 specific T cells, leading the authors to conclude that T cell are essential to controlling COVID-19 disease, and T cell diagnostics could help to predict the course of disease.

Sustained low CD4+ T cell levels are associated with poor COVID-19 prognosis, whilst and increase of T cells during recovery is linked to improved prognosis.

This article considers whether T cells might explain whether an individual develops mild or severe COVID-19 disease, due to the fact that people at higher risk of developing severe disease have been observed to have a greater reduction in T cell numbers during SARS-CoV-2 infection (opinion piece).

Patients who recovered from SARS-CoV-2 17 years ago still have specific T cells against the virus today, suggesting that T cell responses to human coronaviruses may be robust and long-lasting.

Memory T and B cells could be detected in the majority of COVID-19 patients with little or no decay up to 8 months after infection, suggesting that many people will develop strong and long-lasting immune responses to SARS-CoV-2.

Patients who suffer from severe COVID-19 develop stronger T cell responses than those who suffer from mild disease. SARS-CoV-2-specific T cell responses can be detected using ELISpot IGRAs.

SARS-CoV-2-specific T cell responses in infected can be detected using the T-SPOT Discovery SARS-CoV-2 RUO kit, and these T cell responses appear to be associated with protection from COVID-19.

100% of patients who have been exposed to the novel SARS-CoV-2 coronavirus had T cells specific to the virus circulating in their peripheral blood. SARS-CoV-2 specific T cells were also detected in 40-60% of unexposed individuals – suggesting that some people may have pre-existing cross-reactive immune responses to the virus.

SARS-CoV-2-specific T cells were detectable in antibody negative individuals who had suffered from mild or asymptomatic COVID-19. This suggests that T cells may be a more sensitive indicator of exposure to SARS-CoV-2 than antibodies.

Immunologists decode T cell responses that occur during Covid-19 infection.

Individuals who have been infected with the SARS-CoV-2 virus still have detectable T cell responses 6 months after initial infection.

SARS-CoV-2-specific T cell responses many still be present up to 9 months post-infection.

Most SARS-CoV-2 specific CD8+ T cells should maintain recognition of the major SARS-CoV-2 variants.